Recruiting studies: Refractory Langerhans Cell Histiocytosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943224 Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810 Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phase 2 · 12 location(s) · Carl Allen · NCT04079179 Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943198 Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocyt
Phase 2 · 1 location(s) · West China Second University Hospital · NCT07022834 To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Phase 2 · 11 location(s) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd · NCT05997602 A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histioc
Phase 2 · 119 location(s) · National Cancer Institute (NCI) · NCT05828069

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.